As budget discussions heat up in Smith County, officials and department heads are navigating tough decisions within a “bare ...

Orion Group Holdings, Inc. is rated Buy at $8.06/share. Benefit from insights on catalysts like federal initiatives and ...

Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide is the first product candidate to achieve statistically ...

Reached full enrolment of Phase 1b study evaluating GT-02287 in Parkinson’s Disease (PD) with or without GBA1 mutations during 2Q 2025, earlier than anticipated Analysis of functional changes and ...

Kopin Corporation ("Kopin" or "the Company") (Nasdaq: KOPN), a leading developer and provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays, ...